Mexican courts are extending patent protection for key drugs like Denosumab, Bimatoprost, and Semaglutide, creating complex legal battles with generic manufacturers. This situation highlights the tension between pharmaceutical companies seeking to maximize monopoly rights and the push for more accessible generic alternatives.